Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 vs Semaglutide in Chinese Patients with Type 2 Diabetes
NCT06256549Phase 2Active, not recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bofanglutide in type 2 diabetes mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals. Started Aug 2023; status: active, not recruiting.
02
Drugs
bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06256549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256549.